2 studies found for:    NCT00390221
Show Display Options
Rank Status Study
1 Completed Safety and Efficacy Study of Daclizumab High Yield Process to Treat Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-remitting
Interventions: Biological: Daclizumab High Yield Process;   Other: placebo
2 Completed Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Subjects With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis.
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: Daclizumab High Yield Process 150 mg;   Biological: Daclizumab High Yield Process 300 mg

Indicates status has not been verified in more than two years